Short Communication: Low False Recent Rate of Limiting-Antigen Avidity Assay among Long-Term Infected Subjects from Guangxi, China

AIDS Research and Human Retroviruses

Volumn 31, Issue 12, 2015, Pages 1247-1249

  Yu, Li ^a   Laeyendecker, Oliver ^b,c   Wendel, Sarah K ^b   Liang, Fuxiong ^a   Liu, Wei ^a   Wang, Xueyan ^a   Wang, Lu ^a   Pang, Xianwu ^a   Fang, Zhongliao ^a  

^a Institute of Toxicology Guangxi Center for Disease Prevention and Control   (China)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHINA; CHINESE; FALSE RECENT RATE; FEMALE; FREQUENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; LIMITED ANTIGEN AVIDITY ASSAY; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; PRIORITY JOURNAL; PROSTITUTION; SYSTEMATIC ERROR; VIRUS LOAD; ANTIBODY AFFINITY; BLOOD; HIV INFECTIONS; IMMUNOLOGY; MIDDLE AGED; PREVALENCE; SURVIVOR; YOUNG ADULT;

ADULT; ANTIBODY AFFINITY; CHINA; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; SURVIVORS; YOUNG ADULT;

EID: 84948409104     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2015.0097     Document Type: Article

References (10)

1. Incidence Assay Critical Path Working Group: More and better information to tackle HIV epidemics: Towards improved HIVincidence assays. PLoSMed 2011;8(6):e1001045.
2. Mastro TD, Kim AA, Hallett T, et al.: Estimating HIV incidence in populations using tests for recent infection: Issues, challenges and the way forward. J HIV AIDS Surveill Epidemiol 2010;2(1):1-14.
3. Huynh D, Laeyendecker O, and Brookmeyer R: A serial risk score approach to disease classification that accounts for accuracy and cost. Biometrics 2014;70(4):1042-1051.
4. Duong YT, Qiu M, De AK, et al.: Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: Potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One 2012;7(3):e33328.
5. Maxim Biomedical Inc.: Maxim HIV-1 Limiting Antigen Avidity EIA. Rockville, MD, 2013.
6. Duong YT, Kassanjee R, Welte A, et al.: Recalibration of the Limiting Antigen Avidity EIA to determine mean duration of recent infection in divergent HIV-1 subtypes. PLoS One 2015; 10(2): e0114947.
7. Sexton CJ, Costenbader EC, Vinh DT, et al.: Correlation of prospective and cross-sectional measures of HIV type 1 incidence in a higher-risk cohort in Ho Chi Minh City, Vietnam. AIDS Res Hum Retroviruses 2012;28(8): 866-873.
8. Kassanjee R, Pilcher CD, Keating SM, et al.: Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS 2014;28(16): 2439-2449.
9. Li G, Liang S, Harrison TJ, et al.: Prevalence of transmitted HIV-1 drug resistance remains low in Guangxi, China, eight years after scale-up of highly-active antiretroviral therapy. Intervirology 2014;57(5):270-276.
10. Li L, Sun G, Liang S, et al.: Different distribution of HIV-1 subtype and drug resistance were found among treatment naive individuals in Henan, Guangxi, and Yunnan province of China. PLoS One 2013; 8(10):e75777.